Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Inclusion Criteria: * 20 years of age or older * Diagnosis of POAG or OHT in both eyes (POAG in one eye and OHT in the fellow eye was acceptable) * Medicated intraocular pressure (IOP) ≥ 14 mmHg in at least one eye and \< 30 mmHg in both eyes at screening visit * For POAG eyes, unmedicated (post washout) IOP ≥ 15 mmHg and \< 35 mmHg in the study eye at 2 qualification visits (09:00 hours), 2-7 days apart. At second qualification visit IOP ≥ 15 mmHg and \< 35 mmHg at 11:00 and 16:00 hour (in the same eye). * For OHT eyes, unmedicated (post washout) IOP ≥ 22 mmHg and \< 35 mmHg in the study eye at 2 qualification visits (09:00 hours), 2-7 days apart. At second qualification visit IOP ≥ 22 mmHg and \< 35 mmHg at 11:00 and 16:00 hours (in the same eye) * Best-corrected visual acuity (BCVA) +0.7 log MAR or better (20/100 Snellen or better or 0.20 or better in decimal unit) in each eye * Willingness and ability to give signed informed consent and follow study instructions Exclusion Criteria: * Clinically significant ocular disease * Retinal diseases that may progress during the study period * Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles * Previous glaucoma intraocular surgery * Refractive surgery in either eye * Ocular hyperemia score of moderate (+2) or severe (+3) at Qualification Visit #2 * Ocular trauma * Ocular infection or inflammation * Any corneal disease that may confound assessment * Evidence of corneal deposits or cornea verticillata * Known hypersensitivity to any component of netarsudil ophthalmic solution 0.02%, ripasudil hydrochloride hydrate ophthalmic solution 0.4%, or to topical anesthetic. * Mean central corneal thickness \>620 um * Any abnormality preventing reliable Goldmann applanation tonometry of either eye (e.g. keratoconus) * Cannot demonstrate proper delivery of the eye drop * Clinically significant systemic disease * Participation in any investigational study within 30 days prior to screening * Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.